MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome (2024)

Article Navigation

Volume 176 Issue 2 Feb 2017
  • Next >

Journal Article

Get access

,

Dorte Glintborg

Department of Endocrinology, Odense University Hospital

, Odense C,

Denmark

Correspondence should be addressed to D Glintborg; Email: dorte.glintborg@rsyd.dk

Search for other works by this author on:

Oxford Academic

Marianne Andersen

Department of Endocrinology, Odense University Hospital

, Odense C,

Denmark

Search for other works by this author on:

Oxford Academic

European Journal of Endocrinology, Volume 176, Issue 2, Feb 2017, Pages R53–R65, https://doi.org/10.1530/EJE-16-0373

Published:

01 February 2017

Article history

Received:

27 April 2016

Revision received:

17 August 2016

Published:

01 February 2017

  • Views
    • Article contents
    • Figures & tables
    • Video
    • Audio
    • Supplementary Data
  • Cite

    Cite

    Dorte Glintborg, Marianne Andersen, MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome, European Journal of Endocrinology, Volume 176, Issue 2, Feb 2017, Pages R53–R65, https://doi.org/10.1530/EJE-16-0373

    Close

Search

Close

Search

Advanced Search

Search Menu

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition in premenopausal women. The syndrome is characterized by hyperandrogenism, irregular menses and polycystic ovaries when other etiologies are excluded. Obesity, insulin resistance and low vitamin D levels are present in more than 50% patients with PCOS, these factors along with hyperandrogenism could have adverse effects on long-term health. Hyperinflammation and impaired epithelial function were reported to a larger extent in women with PCOS and could particularly be associated with hyperandrogenism, obesity and insulin resistance. Available data from register-based and data linkage studies support that metabolic-vascular and thyroid diseases, asthma, migraine, depression and cancer are diagnosed more frequently in PCOS, whereas fracture risk is decreased. Drug prescriptions are significantly more common in PCOS than controls within all diagnose categories including antibiotics. The causal relationship between PCOS and autoimmune disease represents an interesting new area of research. PCOS is a lifelong condition and long-term morbidity could be worsened by obesity, sedentary way of life, Western-style diet and smoking, whereas lifestyle intervention including weight loss may partly or fully resolve the symptoms of PCOS and could improve the long-term prognosis. In this review, the possible implications of increased morbidity for the clinical and biochemical evaluation of patients with PCOS at diagnosis and follow-up is further discussed along with possible modifying effects of medical treatment.

© European Society of Endocrinology 2017

Issue Section:

Review

You do not currently have access to this article.

Download all slides

Sign in

Get help with access

Personal account

  • Sign in with email/username & password
  • Get email alerts
  • Save searches
  • Purchase content
  • Activate your purchase/trial code

Sign in Register

Institutional access

  1. Sign in through your institution MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome (5)
  2. Sign in with a library card Sign in with username/password Recommend to your librarian

Institutional account management

Sign in as administrator

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

  1. Click Sign in through your institution.
  2. Select your institution from the list provided, which will take you to your institution's website to sign in.
  3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
  4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

  1. Click Sign in through society site.
  2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
  3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

  • View your signed in personal account and access account management features.
  • View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Subscription prices and ordering for this journal

Purchasing options for books and journals across Oxford Academic

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome - 24 Hours access

EUR €30.00

GBP £26.00

USD $32.00

Rental

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome (6)

This article is also available for rental through DeepDyve.

Advertisem*nt intended for healthcare professionals

Citations

Views

140

Altmetric

More metrics information

Metrics

Total Views 140

83 Pageviews

57 PDF Downloads

Since 1/1/2023

Month: Total Views:
January 2023 9
February 2023 14
March 2023 4
April 2023 9
May 2023 3
June 2023 14
August 2023 10
September 2023 5
October 2023 11
November 2023 7
December 2023 23
January 2024 2
February 2024 15
March 2024 5
April 2024 9

Citations

Powered by Dimensions

30 Web of Science

Altmetrics

×

Email alerts

Article activity alert

Advance article alerts

New issue alert

In progress issue alert

Receive exclusive offers and updates from Oxford Academic

Citing articles via

Google Scholar

  • Latest

  • Most Read

  • Most Cited

A novel mutation in the NR3C1 gene associated with reversible glucocorticoid resistance
Frequency of stress dosing and adrenal crisis in paediatric and adult patients with congenital adrenal hyperplasia: a prospective study
Heterozygous gain of function variant in GUCY1A2 may cause autonomous ovarian hyperfunction
Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline
Monitoring adrenal insufficiency through salivary steroids: a pilot study

More from Oxford Academic

Clinical Medicine

Endocrinology and Diabetes

Medicine and Health

Books

Journals

Advertisem*nt intended for healthcare professionals

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome (2024)
Top Articles
Latest Posts
Article information

Author: The Hon. Margery Christiansen

Last Updated:

Views: 5748

Rating: 5 / 5 (70 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: The Hon. Margery Christiansen

Birthday: 2000-07-07

Address: 5050 Breitenberg Knoll, New Robert, MI 45409

Phone: +2556892639372

Job: Investor Mining Engineer

Hobby: Sketching, Cosplaying, Glassblowing, Genealogy, Crocheting, Archery, Skateboarding

Introduction: My name is The Hon. Margery Christiansen, I am a bright, adorable, precious, inexpensive, gorgeous, comfortable, happy person who loves writing and wants to share my knowledge and understanding with you.